Solaris Resources Inc. (CVE:SLS – Free Report) – Research analysts at HC Wainwright lowered their FY2024 earnings estimates for shares of Solaris Resources in a report released on Monday, November 18th. HC Wainwright analyst H. Ihle now forecasts that the company will post earnings per share of ($0.56) for the year, down from their prior estimate of ($0.45). HC Wainwright currently has a “Strong-Buy” rating on the stock. HC Wainwright also issued estimates for Solaris Resources’ FY2025 earnings at ($0.44) EPS.
Solaris Resources Stock Performance
SLS opened at C$6.15 on Wednesday. The firm’s 50 day moving average price is C$6.15. Solaris Resources has a 52-week low of C$1.38 and a 52-week high of C$7.09.
About Solaris Resources
SELLAS Life Sciences Group, Inc, a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer.
Featured Stories
- Five stocks we like better than Solaris Resources
- Best Stocks Under $5.00
- Target Results Are Not a Retail Bellwether: Why the Dip Is a Buy
- The 3 Best Fintech Stocks to Buy Now
- Williams-Sonoma Stock: Buy It and Never Let It Go
- 10 Best Airline Stocks to Buy
- 5 Dividend ETFs to Buy and Hold Forever
Receive News & Ratings for Solaris Resources Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solaris Resources and related companies with MarketBeat.com's FREE daily email newsletter.
